Apellis Pharmaceuticals (NASDAQ:APLS) PT Lowered to $43.00
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price decreased by Wells Fargo & Company from $47.00 to $43.00 in a research report sent to investors on Tuesday morning, Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the stock. A number of other equities research analysts have also commented […]
More Stories
MTY Food Group (TSE:MTY) PT Raised to C$54.00 at National Bankshares
MTY Food Group (TSE:MTY – Get Free Report) had its target price hoisted by analysts at National Bankshares from C$53.00...
TransAlta Co. (TSE:TA) Senior Officer Sells C$278,400.00 in Stock
TransAlta Co. (TSE:TA – Get Free Report) (NYSE:TAC) Senior Officer Jane Nyla Fedoretz sold 20,000 shares of the company’s stock...
Palantir Technologies Inc. (NYSE:PLTR) Director Sells $254,021.35 in Stock
Palantir Technologies Inc. (NYSE:PLTR – Get Free Report) Director Lauren Elaina Friedman Stat sold 6,655 shares of the business’s stock...
Morgan Stanley Boosts Entergy (NYSE:ETR) Price Target to $115.00
Entergy (NYSE:ETR – Free Report) had its price target increased by Morgan Stanley from $109.00 to $115.00 in a research...
BTIG Research Downgrades Global Payments (NYSE:GPN) to Neutral
BTIG Research lowered shares of Global Payments (NYSE:GPN – Free Report) from a buy rating to a neutral rating in...
IDACORP (NYSE:IDA) Price Target Raised to $108.00
IDACORP (NYSE:IDA – Free Report) had its price objective increased by Morgan Stanley from $102.00 to $108.00 in a research...